{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-034283","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2025-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.842279+00:00","generated_at":"2026-05-23T16:18:07.489567+00:00","sec_items":["3.01","3.03","5.03","5.02","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Petros receives Nasdaq equity deficiency delisting notice; shareholders approve massive share increase and reverse split","bullets":["Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.","All delisting actions stayed pending hearing before Nasdaq Hearings Panel; company intends to address concerns.","At special meeting Apr 10, stockholders approved increasing authorized common shares from 250M to 7B.","Also approved reverse stock split at ratio of 1-for-250 to 1-for-500, at Board's discretion.","Approved increase in incentive plan shares by 1B to 1,002,760,000, and issuance of shares underlying Series Warrants from Feb 2025 offering (approx 1.06B shares)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-034283","json":"https://secwatch.observer/filing/0001104659-25-034283.json","markdown":"https://secwatch.observer/filing/0001104659-25-034283.md","text":"https://secwatch.observer/filing/0001104659-25-034283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/0001104659-25-034283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/tm2512195d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T16:18:07.489567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d6be27c9c4eca6654d385347abacbbf1c6613e8","claim":"Petros Pharmaceuticals, Inc.: Increased authorized shares of Common Stock from 250,000,000 to 7,000,000,000 and made a corresponding change to total authorized capital stock shares (effective 2025-04-11).","evidence_excerpt":"the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Share Increase Amendment”) to increase the number of authorized shares of the Common Stock from 250,000,000 shares to 7,000,000,000","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/0001104659-25-034283-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-04-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}